BeiGene, Ltd. Initial Public Offering and NASDAQ Listing

Davis Polk advised the joint book-running managers and representatives of the underwriters in the $182.2 million initial public offering by BeiGene, Ltd. of 7,590,000 American Depositary Shares. The ADSs are listed on the NASDAQ Global Select Market under the symbol “BGNE”.

BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics.

The Davis Polk corporate team included partners Bruce K. Dallas and James C. Lin and associates Jeannette K. Safi, Tyler P. Pender, Adam H. Whitaker and Randy Li. Partner John D. Paton and associate Omer Harel provided tax advice. The intellectual property and technology team included partner Pritesh P. Shah. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California, New York and London offices.